CDKN2A缺失与101例成人T细胞急性淋巴细胞白血病的不良预后相关
该研究在101例成人T-ALL患者中通过FISH检测CDKN2A缺失,发现缺失率为23%,以纯合缺失为主。CDKN2A缺失与年轻、高白细胞计数和高LDH水平相关,且患者2年OS和EFS显著降低,多因素分析显示其为OS的独立不良预后因素。
要点
- 成人T-ALL中CDKN2A缺失率为23%,纯合缺失占70%。
- CDKN2A缺失者2年OS和EFS显著低于无缺失者。
- CDKN2A缺失是OS的独立不良预后因素。
核心结论
- 成人T-ALL患者中CDKN2A缺失提示预后不良,可能受益于强化化疗或异基因造血干细胞移植。
研究设计与样本
- 回顾性研究,纳入101例成人T-ALL患者,采用FISH检测CDKN2A缺失。
主要发现
- CDKN2A缺失率为23%(23/101),纯合缺失占70%(16/23)。
- ETP-ALL患者CDKN2A缺失频率低于非ETP-ALL(10.4% vs 34.0%;P = .008)。
- CDKN2A缺失与年轻年龄(P = .001)、高白细胞计数(P < .001)和高LDH水平(P = .002)相关。
- CDKN2A缺失者2年OS为18.6% ± 8.9% vs 47.4% ± 6.2%(P = .032),EFS为16.4 ± 8.3 vs 38.6 ± 5.9%(P = .022)。
- 多因素分析显示CDKN2A缺失是OS的独立不良预后因素(P = .016)。
临床怎么用
- 对成人T-ALL患者可考虑检测CDKN2A缺失以辅助风险分层。
- CDKN2A缺失患者可能需要强化化疗或异基因造血干细胞移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The identification of genetic risk subgroups of T-cell acute lymphoblastic leukemia (T-ALL) may provide evidence for risk stratification and individualized treatment. We investigated the characteristics and prognostic value of tumor suppressor gene CDKN2A deletions in 101 patients with T-ALL. The CDKN2A deletion was present in 23% (23/101) of T-ALL by fluorescence in situ hybridization (FISH). The most common type of CDKN2A deletion was homozygous deletion (70%, 16/23). A lower frequency of CDKN2A deletion was found in patients with early T-cell precursor (ETP) ALL than in patients with non-ETP-ALL (10.4% vs 34.0%; P = .008). Deletion of CDKN2A was significantly associated with younger age (P = .001), higher white blood cell (WBC) count (P < .001) and higher lactate dehydrogenase (LDH) level (P = .002). Patients with CDKN2A deletion had lower 2-year overall survival (OS) and event-free survival (EFS) rates than patients without CDKN2A deletion (2-year OS: 18.6% ± 8.9% vs 47.4% ± 6.2%, P = .032; EFS: 16.4 ± 8.3 vs 38.6 ± 5.9%, P = .022). In multivariable analysis, CDKN2A deletion was an independent adverse prognostic factor for OS (P = .016). In conclusion, adult T-ALL patients with CDKN2A deletion had a poor prognosis, and these patients might benefit from intensive chemotherapy or allogeneic hematopoietic stem-cell transplantation.
引用
- Wang HP, Zhou YL, Huang X, et al. CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. Am J Hematol. 2020. PMID: 33306218. doi:10.1002/ajh.26069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。